Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management

<table>Papulopustular eruption. A 52-year-old man with non-small-cell lung carcinoma stage IV developed papulopustules 6 days after erlotinib was commenced.</table>

Dermatology Research and Practice

fig1

Figure 1

Figure 1: Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management 